Protein Engineering, Vol. 12, No. 9, 771-778,
September 1999
© 1999 Oxford University Press
Design, engineering and production of functional single-chain T cell receptor ligands
1 Department of Neurology, 2 Department of Biochemistry and Molecular Biology and 4 Department of Molecular Microbiology and Immunology, Oregon Health Sciences University, 3 Neuroimmunology Research and 6 Neurology Service, Veterans Affairs Medical Center and 5 Shriners Hospital for Children, Portland, Oregon 97201, USA
Major histocompatibility complex (MHC) class II molecules are membrane-anchored heterodimers on the surface of antigen presenting cells (APCs) that bind the T cell receptor, initiating a cascade of interactions that results in antigen-specific activation of clonal populations of T cells. The peptide binding/T cell recognition domains of rat MHC class II (alpha-1 and beta-1 domains) were expressed as a single exon for structural and functional characterization. These recombinant single-chain T cell receptor ligands (termed `ß1
1' molecules) of approximately 200 amino acid residues were designed using the structural backbone of MHC class II molecules as template, and have been produced in Escherichia coli with and without N-terminal extensions containing antigenic peptides. Structural characterization using circular dichroism predicted that these molecules retained the antiparallel ß-sheet platform and antiparallel
-helices observed in the native MHC class II heterodimer. The proteins exhibited a cooperative two-state thermal foldingunfolding transition. ß1
1 molecules with a covalently linked MBP-7289 peptide showed increased stability to thermal unfolding relative to the empty ß1
1 molecules. This new class of small soluble polypeptide provides a template for designing and refining human homologues useful in detecting and regulating pathogenic T cells.
Keywords: ß1
1/drug design/immunotherapy/MHC class II/TCR ligand
4 To whom correspondence should be addressed
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
S. Subramanian, B. Zhang, Y. Kosaka, G. G. Burrows, M. R. Grafe, A. A. Vandenbark, P. D. Hurn, and H. Offner Recombinant T Cell Receptor Ligand Treats Experimental Stroke Stroke, July 1, 2009; 40(7): 2539 - 2545. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sinha, S. Subramanian, L. Miller, T. M. Proctor, C. Roberts, G. G. Burrows, A. A. Vandenbark, and H. Offner Cytokine Switch and Bystander Suppression of Autoimmune Responses to Multiple Antigens in Experimental Autoimmune Encephalomyelitis by a Single Recombinant T-Cell Receptor Ligand J. Neurosci., March 25, 2009; 29(12): 3816 - 3823. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Huan, L. J. Kaler, J. L. Mooney, S. Subramanian, C. Hopke, A. A. Vandenbark, E. F. Rosloniec, G. G. Burrows, and H. Offner MHC Class II Derived Recombinant T Cell Receptor Ligands Protect DBA/1LacJ Mice from Collagen-Induced Arthritis J. Immunol., January 15, 2008; 180(2): 1249 - 1257. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sinha, S. Subramanian, T. M. Proctor, L. J. Kaler, M. Grafe, R. Dahan, J. Huan, A. A. Vandenbark, G. G. Burrows, and H. Offner A Promising Therapeutic Approach for Multiple Sclerosis: Recombinant T-Cell Receptor Ligands Modulate Experimental Autoimmune Encephalomyelitis by Reducing Interleukin-17 Production and Inhibiting Migration of Encephalitogenic Cells into the CNS J. Neurosci., November 14, 2007; 27(46): 12531 - 12539. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Fontenot, T. S. Keizer, M. McCleskey, D. G. Mack, R. Meza-Romero, J. Huan, D. M. Edwards, Y. K. Chou, A. A. Vandenbark, B. Scott, et al. Recombinant HLA-DP2 Binds Beryllium and Tolerizes Beryllium-Specific Pathogenic CD4+ T Cells J. Immunol., September 15, 2006; 177(6): 3874 - 3883. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. L. Jones, S. E. Brophy, A. J. Bankovich, L. A. Colf, N. A. Hanick, K. C. Garcia, and D. M. Kranz Engineering and Characterization of a Stabilized {alpha}1/{alpha}2 Module of the Class I Major Histocompatibility Complex Product Ld J. Biol. Chem., September 1, 2006; 281(35): 25734 - 25744. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Adamus, G. G. Burrows, A. A. Vandenbark, and H. Offner Treatment of Autoimmune Anterior Uveitis with Recombinant TCR Ligands. Invest. Ophthalmol. Vis. Sci., June 1, 2006; 47(6): 2555 - 2561. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Offner, S. Subramanian, C. Wang, M. Afentoulis, A. A. Vandenbark, J. Huan, and G. G. Burrows Treatment of Passive Experimental Autoimmune Encephalomyelitis in SJL Mice with a Recombinant TCR Ligand Induces IL-13 and Prevents Axonal Injury J. Immunol., September 15, 2005; 175(6): 4103 - 4111. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Huan, S. Subramanian, R. Jones, C. Rich, J. Link, J. Mooney, D. N. Bourdette, A. A. Vandenbark, G. G. Burrows, and H. Offner Monomeric Recombinant TCR Ligand Reduces Relapse Rate and Severity of Experimental Autoimmune Encephalomyelitis in SJL/J Mice through Cytokine Switch J. Immunol., April 1, 2004; 172(7): 4556 - 4566. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Wang, J. L. Mooney, R. Meza-Romero, Y. K. Chou, J. Huan, A. A. Vandenbark, H. Offner, and G. G. Burrows Recombinant TCR Ligand Induces Early TCR Signaling and a Unique Pattern of Downstream Activation J. Immunol., August 15, 2003; 171(4): 1934 - 1940. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. McMahan, L. Watson, R. Meza-Romero, G. G. Burrows, D. N. Bourdette, and A. C. Buenafe Production, Characterization, and Immunogenicity of a Soluble Rat Single Chain T Cell Receptor Specific for an Encephalitogenic Peptide J. Biol. Chem., August 15, 2003; 278(33): 30961 - 30970. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Vandenbark, C. Rich, J. Mooney, A. Zamora, C. Wang, J. Huan, L. Fugger, H. Offner, R. Jones, and G. G. Burrows Recombinant TCR Ligand Induces Tolerance to Myelin Oligodendrocyte Glycoprotein 35-55 Peptide and Reverses Clinical and Histological Signs of Chronic Experimental Autoimmune Encephalomyelitis in HLA-DR2 Transgenic Mice J. Immunol., July 1, 2003; 171(1): 127 - 133. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. G. Burrows, Y. K. Chou, C. Wang, J. W. Chang, T. P. Finn, N. E. Culbertson, J. Kim, D. N. Bourdette, D. A. Lewinsohn, D. M. Lewinsohn, et al. Rudimentary TCR Signaling Triggers Default IL-10 Secretion by Human Th1 Cells J. Immunol., October 15, 2001; 167(8): 4386 - 4395. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. G. Burrows, K. L. Adlard, B. F. Bebo Jr., J. W. Chang, K. Tenditnyy, A. A. Vandenbark, and H. Offner Regulation of Encephalitogenic T Cells with Recombinant TCR Ligands J. Immunol., June 15, 2000; 164(12): 6366 - 6371. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Chang, D. E. Mechling, H.-P. Bachinger, and G. G. Burrows Design, Engineering, and Production of Human Recombinant T Cell Receptor Ligands Derived from Human Leukocyte Antigen DR2 J. Biol. Chem., June 22, 2001; 276(26): 24170 - 24176. [Abstract] [Full Text] [PDF] |
||||




